Durable response to capecitabine plus pembrolizumab in synchronous intrahepatic cholangiocarcinoma and gastric adenocarcinoma: a case report

Background Multiple primary malignancies (MPMs) are uncommon, and synchronous occurrence of gastric cancer with intrahepatic cholangiocarcinoma (ICC) is extremely rare, with only isolated case reports documented. Most reported cases were managed surgically, and data on systemic therapy remain limited, with no established treatment guidelines for this specific population. Case presentation An asymptomatic 87-year-old female was diagnosed with synchronous poorly differentiated ICC and primary gastric adenocarcinoma. Next-generation sequencing of the hepatic lesion revealed an FGFR3-TACC3 fusion and a high Ki-67 index of 70%, with low tumor mutational burden and microsatellite stable status. The gastric tumor was proficient mismatch repair (pMMR) and HER2-negative. Due to her advanced age and refusal of standard intravenous chemotherapy, she received a low-toxicity regimen of oral capecitabine (1,000 mg/m² orally twice daily on days 1–14) and intravenous pembrolizumab (200 mg on day 1) in 21-day cycles. Remarkably, the patient achieved a sustained radiographic partial response, with a progression-free survival (PFS) of 38.7 months as of the last radiological assessment on June 18, 2026. The treatment was generally well tolerated, with grade 1 hand-foot syndrome and grade 1 leukopenia and no grade 3 or higher adverse events. Conclusion This is the first reported case of synchronous intrahepatic cholangiocarcinoma and gastric adenocarcinoma showing durable response to pembrolizumab plus capecitabine.

Authors

Institutions

Publication Details

Journal
Frontiers in Oncology
Published
2026-11-12
DOI
https://doi.org/10.3389/fonc.2026.1990743
Primary Topic
Multiple and Secondary Primary Cancers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Durable response to capecitabine plus pembrolizumab in synchronous intrahepatic cholangiocarcinoma and gastric adenocarcinoma: a case report

Xiaofen Li, Sirong Tao, Xiaorui Zhu, Cheng Yi et al.
Frontiers in Oncology
Multiple and Secondary Primary Cancers
article

Durable response to capecitabine plus pembrolizumab in synchronous intrahepatic cholangiocarcinoma and gastric adenocarcinoma: a case report

Xiaofen Li, Sirong Tao, Xiaorui Zhu, Cheng Yi, Dan Cao, Jiaxin Liu
article en

Abstract

Background Multiple primary malignancies (MPMs) are uncommon, and synchronous occurrence of gastric cancer with intrahepatic cholangiocarcinoma (ICC) is extremely rare, with only isolated case reports documented. Most reported cases were managed surgically, and data on systemic therapy remain limited, with no established treatment guidelines for this specific population. Case presentation An asymptomatic 87-year-old female was diagnosed with synchronous poorly differentiated ICC and primary gastric adenocarcinoma. Next-generation sequencing of the hepatic lesion revealed an FGFR3-TACC3 fusion and a high Ki-67 index of 70%, with low tumor mutational burden and microsatellite stable status. The gastric tumor was proficient mismatch repair (pMMR) and HER2-negative. Due to her advanced age and refusal of standard intravenous chemotherapy, she received a low-toxicity regimen of oral capecitabine (1,000 mg/m² orally twice daily on days 1–14) and intravenous pembrolizumab (200 mg on day 1) in 21-day cycles. Remarkably, the patient achieved a sustained radiographic partial response, with a progression-free survival (PFS) of 38.7 months as of the last radiological assessment on June 18, 2026. The treatment was generally well tolerated, with grade 1 hand-foot syndrome and grade 1 leukopenia and no grade 3 or higher adverse events. Conclusion This is the first reported case of synchronous intrahepatic cholangiocarcinoma and gastric adenocarcinoma showing durable response to pembrolizumab plus capecitabine.

Frontiers in OncologyVol. 16
Sichuan University (CN), West China Second University Hospital of Sichuan University (CN), West China Hospital of Sichuan University (CN), State Key Laboratory of Biotherapy (CN)
Good health and well-being
Multiple and Secondary Primary Cancers
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon